Each order of AndroNorth Orforglipron 6mg contains one (1) satchet of sixty (60) tablets, each containing 6mg milligrams of highly pure Orforglipron.
Orforglipron tablets are an investigational, once-daily, orally administered small-molecule therapy being developed for the treatment of chronic metabolic diseases, including obesity and type 2 diabetes. Unlike injectable incretin therapies, orforglipron is designed as a non-peptide oral agent, offering the potential convenience of tablet dosing while targeting established metabolic pathways.
Orforglipron acts as a glucagon-like peptide-1 (GLP-1) receptor agonist, a mechanism known to support glycemic control and body-weight reduction through effects on appetite regulation, gastric emptying, and insulin secretion. Its small-molecule structure is intended to provide consistent oral bioavailability without the need for injection or complex administration requirements.
